Effect of Enteral Formula (Commercial vs. Homemade) on Muscle Mass in Trauma Brain Injury
Effect of Enteral Polymeric Formulas (Commercial and Homemade Formula) on Muscle Mass in Adults With Trauma Brain Injury
1 other identifier
interventional
39
1 country
1
Brief Summary
This randomized controlled clinical trial aims to determine whether there are differences in muscle mass (MM) in patients with traumatic brain injury who receive enteral nutrition based on polymeric formulas (homemade formula with blended natural foods versus commercial formulas).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jun 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 26, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
March 30, 2025
CompletedFirst Submitted
Initial submission to the registry
April 22, 2025
CompletedFirst Posted
Study publicly available on registry
April 29, 2025
CompletedMay 1, 2025
April 1, 2025
1.8 years
April 22, 2025
April 28, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Femoral muscle (total femoral thickness, rectus femoris vastus intermedius) ultrasound
Ultrasound-guided assessment of femoral muscle thickness. A certified intensivist physician accredited by the World Interactive Network Focused On Critical UltraSound, will perform duplicate measurements of muscle thicknesses (total femoral thickness, rectus femoris, and vastus intermedius) at the midpoint and one-third point of the distance between the superior border of the patella and the anterior superior iliac spine. The linear transducer will be positioned at a 90° angle to the thigh, without applying pressure (no compression). The average of the four measurements will then be calculated.
Change from baseline to end of study, an average of 10 days, with three measurements during follow-up (baseline, 5 days, and 10 days)
Secondary Outcomes (1)
Phase angle
Change from baseline to end of study, an average of 10 days, with three measurements during follow-up (baseline, 5 days, and 10 days)
Study Arms (2)
Homemade formula
OTHERPatients receiving homemade formula made with natural food and will be administered according to the study protocol
Commercial enteral formula
OTHERPatients receiving commercial formula and will be administered according to the study protocol.
Interventions
Patients will receive enteral feeding with a polymeric formula made from blended natural foods (apple, chayote, cookie, chicken and olive oil), adjusted to meet their nutritional requirements (energy: 25 kcal/kg, protein: 1.3 g/kg).
Patients will receive enteral feeding with a commercial polymeric formula, adjusted to meet their nutritional requirements (energy: 25 kcal/kg, protein: 1.3 g/kg).
Eligibility Criteria
You may qualify if:
- Age: ≥ 18 years - 65 years
- Sex: Both sexes
- Moderate/severe TBI (Glasgow \<13 points) admitted to the ICU
- Invasive mechanical ventilation \>48 hours
- Candidates for enteral nutrition via nasogastric/orogastric tube
You may not qualify if:
- Pregnant women
- Patients with pacemakers
- Food allergies: egg, chicken, fish, nuts, or lactose intolerance
- Brain death
- Limb amputation or presence of external limb fixators
- Elimination criteria:
- Withdrawal of consent
- Transfer to another healthcare institution.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hospital General "Dr. Miguel Silva"
Morelia, Michoacán, 58253, Mexico
Related Publications (11)
Compher C, Bingham AL, McCall M, Patel J, Rice TW, Braunschweig C, McKeever L. Guidelines for the provision of nutrition support therapy in the adult critically ill patient: The American Society for Parenteral and Enteral Nutrition. JPEN J Parenter Enteral Nutr. 2022 Jan;46(1):12-41. doi: 10.1002/jpen.2267. Epub 2022 Jan 3.
PMID: 34784064BACKGROUNDBechtold ML, Brown PM, Escuro A, Grenda B, Johnston T, Kozeniecki M, Limketkai BN, Nelson KK, Powers J, Ronan A, Schober N, Strang BJ, Swartz C, Turner J, Tweel L, Walker R, Epp L, Malone A; ASPEN Enteral Nutrition Committee. When is enteral nutrition indicated? JPEN J Parenter Enteral Nutr. 2022 Sep;46(7):1470-1496. doi: 10.1002/jpen.2364. Epub 2022 Jul 15.
PMID: 35838308BACKGROUNDKatari Y, Srinivasan R, Arvind P, Hiremathada S. Point-of-Care Ultrasound to Evaluate Thickness of Rectus Femoris, Vastus Intermedius Muscle, and Fat as an Indicator of Muscle and Fat Wasting in Critically Ill Patients in a Multidisciplinary Intensive Care Unit. Indian J Crit Care Med. 2018 Nov;22(11):781-788. doi: 10.4103/ijccm.IJCCM_394_18.
PMID: 30598564BACKGROUNDNascimento TS, de Queiroz RS, Ramos ACC, Martinez BP, Da Silva E Silva CM, Gomes-Neto M. Ultrasound Protocols to Assess Skeletal and Diaphragmatic Muscle in People Who Are Critically Ill: A Systematic Review. Ultrasound Med Biol. 2021 Nov;47(11):3041-3067. doi: 10.1016/j.ultrasmedbio.2021.06.017. Epub 2021 Aug 18.
PMID: 34417065BACKGROUNDEpp L, Blackmer A, Church A, Ford I, Grenda B, Larimer C, Lewis-Ayalloore J, Malone A, Pataki L, Rempel G, Washington V; ASPEN Enteral Nutrition Committee. Blenderized tube feedings: Practice recommendations from the American Society for Parenteral and Enteral Nutrition. Nutr Clin Pract. 2023 Dec;38(6):1190-1219. doi: 10.1002/ncp.11055. Epub 2023 Oct 3.
PMID: 37787762BACKGROUNDBlenderized Feeding Options - The Sky's the Limit. Epp, L. June 2018, Practical Gastroenterology , pp. 30-39
BACKGROUNDVoskuil C, Dudar M, Zhang Y, Carr J. Skeletal Muscle Ultrasonography and Muscle Fitness Relationships: Effects of Scanning Plane and Echogenicity Correction. Muscles. 2023 Mar 23;2(2):109-118. doi: 10.3390/muscles2020010.
PMID: 40757563BACKGROUNDFazzini B, Markl T, Costas C, Blobner M, Schaller SJ, Prowle J, Puthucheary Z, Wackerhage H. The rate and assessment of muscle wasting during critical illness: a systematic review and meta-analysis. Crit Care. 2023 Jan 3;27(1):2. doi: 10.1186/s13054-022-04253-0.
PMID: 36597123BACKGROUNDKalra S, Malik R, Singh G, Bhatia S, Al-Harrasi A, Mohan S, Albratty M, Albarrati A, Tambuwala MM. Pathogenesis and management of traumatic brain injury (TBI): role of neuroinflammation and anti-inflammatory drugs. Inflammopharmacology. 2022 Aug;30(4):1153-1166. doi: 10.1007/s10787-022-01017-8. Epub 2022 Jul 8.
PMID: 35802283BACKGROUNDKhellaf A, Khan DZ, Helmy A. Recent advances in traumatic brain injury. J Neurol. 2019 Nov;266(11):2878-2889. doi: 10.1007/s00415-019-09541-4. Epub 2019 Sep 28.
PMID: 31563989BACKGROUNDBailes JE, Borlongan CV. Traumatic brain injury. CNS Neurosci Ther. 2020 Jun;26(6):593-594. doi: 10.1111/cns.13397. No abstract available.
PMID: 32452140BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Masking Details
- Both the patient and the principal investigator will be blinded to the assigned formula. A hospital nutritionist will be responsible for the prescription and progression according to the proposed requirements and the tolerance of the assigned formula.
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Karina Aguilar Gutiérrez
Study Record Dates
First Submitted
April 22, 2025
First Posted
April 29, 2025
Study Start
June 26, 2023
Primary Completion
March 30, 2025
Study Completion
March 30, 2025
Last Updated
May 1, 2025
Record last verified: 2025-04
Data Sharing
- IPD Sharing
- Will not share
No, individual participant data (IPD) will not be shared with other researchers. The data collected are part of a small-scale, single-center study involving vulnerable patients in critical care. Due to concerns about patient confidentiality, limited sample size, and the absence of prior consent for data sharing beyond the original study scope, we have decided not to make IPD publicly available.